Efficacy of rosuvastatin for the treatment of non‐alcoholic steatohepatitis with dyslipidemia: An open‐label, pilot study

Hyogo, Hideyuki; Ikegami, Tadashi; Tokushige, Katsutoshi; Hashimoto, Etsuko; Inui, Kentaro; Matsuzaki, Yasushi; Tokumo, Hironori; Hino, Fumiaki; Tazuma, Susumu

doi:10.1111/j.1872-034x.2012.01034.x

Cited by 62 publications

(28 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Firstly, it may be due to the lack of initiative by the physician. 13 Although there are several retrospective studies and small, single-arm, open-label pilot studies that have suggested the potential role of statin in the treatment of NAFLD or NASH, [26][27][28][29] there are to date no randomized controlled trial supporting the use of statin to treat NAFLD or NASH specifically. Secondly, physicians and patients may be concerned about the potential adverse effects of statins, which may include myopathy, new-onset diabetes mellitus, and probably hemorrhagic strokes.…”

Section: Discussionmentioning

confidence: 99%

Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease

Khoo

Wong

Goh

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim Nonalcoholic fatty liver disease (NAFLD) patients often have dyslipidemia, and optimal treatment of dyslipidemia lowers the risk of cardiovascular disease and mortality. Our aim was to study the prescription of statin and low‐density lipoprotein cholesterol treatment targets in NAFLD patients. Methods Consecutive NAFLD patients attending five clinics in Asia were included in this study. The 10‐year cardiovascular disease risk was calculated based on the Framingham Heart Study, and patients were categorized as moderate, high, or very high risk for cardiovascular disease on the basis of the American Association of Clinical Endocrinologist 2017 Guidelines. The low‐density lipoprotein cholesterol treatment goal for each of the risk groups was 2.6, 2.6, and 1.8 mmol/L, respectively. Results The data for 428 patients were analyzed (mean age 54.4 ± 11.1 years, 52.1% male). Dyslipidemia was seen in 60.5% (259/428), but only 43.2% (185/428) were on a statin. The percentage of patients who were at moderate, high, and very high risk for cardiovascular disease was 36.7% (157/428), 27.3% (117/428), and 36.0% (154/428), respectively. Among patients who were on a statin, 58.9% (109/185) did not achieve the treatment target. Among patients who were not on a statin, 74.1% (180/243) should be receiving statin therapy. The percentage of patients who were not treated to target or who should be on statin was highest among patients at very high risk for cardiovascular disease at 79.6% (78/98) or 94.6% (53/56), respectively. Conclusion This study highlights the suboptimal treatment of dyslipidemia and calls for action to improve the treatment of dyslipidemia in NAFLD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease

Khoo

Wong

Goh

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…In some studies, an improvement in inflammation was also observed [41,47,49] but not in others [45,48,76]. However, fibrosis was not reduced in any study [41,45,47,48,76] except in a small preliminary report in 6 patients treated with rosuvastatin for 6 months [49]. In contrast, in the only placebocontrolled study with repeat biopsy in patients with NAFLD (n = 16), treatment with simvastatin 40 mg/day for 12 months had no effect on liver histology [53].…”

Section: Accepted Manuscriptmentioning

confidence: 92%

“…Most showed that treatment with statins reduces hepatic steatosis [41,45,47,49] but in some there was no change [48,76]. In some studies, an improvement in inflammation was also observed [41,47,49] but not in others [45,48,76].…”

Section: Accepted Manuscriptmentioning

confidence: 93%

Nonalcoholic fatty liver disease and statins

et al. 2015

View full text Add to dashboard Cite

“…On the contrary it showed a significant decrease in transaminases with atorvastatin treatment. The efficacy of rosuvastatin was also observed in patients with hyperlipidaemia, as well as fatty liver and cardiovascular risk reduction (50). It remains to be shown whether liver fibrosis is favourably affected by treatment with statins (51).…”

Section: Lipid-lowering Drugs: Statinsmentioning

confidence: 99%

Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease

Martín-Domínguez¹,

González-Casas

Mendoza-Jiménez-Ridruejo

et al. 2013

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) includes a broad spectrum of alterations that go from simple steatosis to steatohepatitis and cirrhosis. Type 2 diabetes mellitus (DM-2) and obesity are the principle factors associated to NAFLD. A 20-30 % prevalence in general population has been described. The survival of this type of patient is lower than the general population's, showing a higher incidence of hepatic and cardiovascular complications. The aetiopathogenesis is still unclear, but we know the intervention of different factors that produce fatty-acid accumulation in hepatic parenchyma, causing oxidative stress, oxygen-free radicals and the synthesis of an inflammatory cascade, that determine the progression of this disease from steatosis up to advanced fibrosis.The diagnostic gold-standard is still the liver biopsy, even though the development of newer non-invasive techniques, like serological and imaging (radiology), have opened a new field for research that allows bloodless testing of these patients and better study of the natural history of this disease. Nowadays, there is still no specific treatment for NAFLD. The development of healthy life habits and moderate exercise continue to be the pillars of treatment. Different pharmacological approaches have been studied and applied, such as the control of insulin resistance, lowering cholesterol levels, antioxidants, and other alternatives in experimental trials.

show abstract

Efficacy of rosuvastatin for the treatment of non‐alcoholic steatohepatitis with dyslipidemia: An open‐label, pilot study

Cited by 62 publications

References 59 publications

Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease

Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease and statins

Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease

Contact Info

Product

Resources

About